Can cancer drugs treat immunodeficiency?

Science

Volumn 342, Issue 6160, 2013, Pages 814-815

  Conley, Mary Ellen ^a   Fruman, David A ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; HETERODIMER; IDELALISIB; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PROTEIN P110; PROTEIN P110 ALPHA; PROTEIN P110 BETA; PROTEIN P110 DELTA; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CD PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE;

CANCER; DISEASE TREATMENT; DRUG; GENETIC ANALYSIS; GENOME; GENOMICS;

AGAMMAGLOBULINEMIA; ALEXANDER DISEASE; ANGIOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL LINEAGE; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; E1021K GENE; EMBRYO DEATH; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXOME; GAIN OF FUNCTION MUTATION; GENE; GENE MUTATION; HETEROZYGOSITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INTRACELLULAR SIGNALING; LUNG DISEASE; LYMPHADENOPATHY; NEUTROPHIL; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PIK3CD GENE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RECURRENT INFECTION; REGULATORY MECHANISM; RESPIRATORY TRACT INFECTION; SHORT SURVEY; SPLENOMEGALY; STOP CODON; T LYMPHOCYTE; GENETIC PREDISPOSITION; GENETICS; NOTE; PATHOLOGY;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; PHOSPHATIDYLINOSITOL 3-KINASES; RESPIRATORY TRACT INFECTIONS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84887796170     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1246760     Document Type: Short Survey

References (15)

1. I. Angulo et al., Science 342, 866 (2013); 10.1126/science.1243292.
2. B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera, B. Bilanges, Nat. Rev. Mol. Cell Biol. 11, 329 (2010).
3. E. Clayton et al., J. Exp. Med. 196, 753 (2002).
4. S. T. Jou et al., Mol. Cell. Biol. 22, 8580 (2002).
5. K. Okkenhaug et al., Science 297, 1031 (2002).
6. D. A. Fruman et al., Science 283, 393 (1999).
7. H. Suzuki et al., Science 283, 390 (1999).
8. M. E. Conley et al., J. Exp. Med. 209, 463 (2012).
9. P. Liu, H. Cheng, T. M. Roberts, J. J. Zhao, Nat. Rev. Drug Discov. 8, 627 (2009).
10. M. J. Lindhurst et al., Nat. Genet. 44, 928 (2012).
11. J. B. Rivière et al., Nat. Genet. 44, 934 (2012).
12. J. H. Lee et al., Nat. Genet. 44, 941 (2012).
13. C. L. Lucas et al., Nat. Immunol. 10.103/ni.2771 (2013).
14. D. A. Fruman, C. Rommel, Cancer Discov. 1, 562 (2011).
15. K. D. Puri, M. R. Gold, Front. Immunol. 3, 256 (2012).